Advertisement
Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow My Folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zandi, P. P.
Right arrow Articles by Breitner, J. C.S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zandi, P. P.
Right arrow Articles by Breitner, J. C.S.
Related Collections
Right arrow All Cognitive Disorders/Dementia
Right arrow Alzheimer's disease
Right arrow All epidemiology
Right arrow Risk factors in epidemiology

Neurology 2002;59:880-886
© 2002 American Academy of Neurology

Reduced incidence of AD with NSAID but not H2 receptor antagonists

The Cache County Study
Peter P. Zandi, PhD, James C. Anthony, PhD, Kathleen M. Hayden, MA, Kala Mehta, DSc, Lawrence Mayer, MD and John C.S. Breitner, MD for the Cache County Study Investigators*

From the Department of Mental Hygiene (Drs. Zandi, Anthony, Mehta, Mayer, and Breitner, and K.M. Hayden), Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD; Banner Health System (Dr. Mayer), Phoenix, AZ; and VA Puget Sound Health Care System and Department of Psychiatry and Behavioral Sciences (Dr. Breitner), University of Washington, Seattle, WA.

Address correspondence and reprint requests to Dr. John Breitner, GRECC (S-182), VA Puget Sound Health Care System, 1660 South Columbian Way, Seattle, WA 98108; e-mail: jcsb{at}u.washington.edu

Background: Previous analyses from the Cache County (UT) Study showed inverse associations between the prevalence of AD and the use of nonsteroidal anti-inflammatory drugs (NSAID), aspirin compounds, or histamine H2 receptor antagonists (H2RA). The authors re-examined these associations using data on incident AD.

Methods: In 1995 to 1996, elderly (aged 65+) county residents were assessed for dementia, with current and former use of NSAID, aspirin, and H2RA as well as three other "control" medication classes also noted. Three years later, interval medication histories were obtained and 104 participants with incident AD were identified among 3,227 living participants. Discrete time survival analyses estimated the risk of incident AD in relation to medication use.

Results: AD incidence was marginally reduced in those reporting NSAID use at any time. Increased duration of use was associated with greater risk reduction, and the estimated hazard ratio was 0.45 with >=2 years of exposure. Users of NSAID at baseline showed little reduction in AD incidence, regardless of use thereafter. By contrast, former NSAID users showed substantially reduced incidence (estimated hazard ratio = 0.42), with a trend toward greatest risk reduction among those with extended exposure. Similar patterns appeared with aspirin but not with any other medicines examined.

Conclusions: Long-term NSAID use may reduce the risk of AD, provided such use occurs well before the onset of dementia. More recent exposure seems to offer little protection. Recently initiated randomized trials of NSAID for primary prevention of AD are therefore unlikely to show effects with treatment until participants have been followed for several years.




This article has been cited by other articles:


Home page
 NeurologyHome page
C. Sanz, S. Andrieu, A. Sinclair, H. Hanaire, B. Vellas, and For the REAL.FR Study Group
Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease
Neurology, October 27, 2009; 73(17): 1359 - 1366.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J.C.S. Breitner, S. J.P.A. Haneuse, R. Walker, S. Dublin, P. K. Crane, S. L. Gray, and E. B. Larson
Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort
Neurology, June 2, 2009; 72(22): 1899 - 1905.
[Abstract] [Full Text] [PDF]

Home page
 Epidemiol RevHome page
N. Coley, S. Andrieu, V. Gardette, S. Gillette-Guyonnet, C. Sanz, B. Vellas, and A. Grand
Dementia Prevention: Methodological Explanations for Inconsistent Results
Epidemiol. Rev., November 1, 2008; 30(1): 35 - 66.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
H. L. Haas, O. A. Sergeeva, and O. Selbach
Histamine in the Nervous System
Physiol Rev, July 1, 2008; 88(3): 1183 - 1241.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
ADAPT Research Group
Cognitive Function Over Time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): Results of a Randomized, Controlled Trial of Naproxen and Celecoxib
Arch Neurol, July 1, 2008; 65(7): 896 - 905.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
C. A. Szekely, R. C. Green, J.C.S. Breitner, T. Ostbye, A. S. Beiser, M. M. Corrada, H. H. Dodge, M. Ganguli, C. H. Kawas, L. H. Kuller, et al.
No advantage of A{beta}42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies
Neurology, June 10, 2008; 70(24): 2291 - 2298.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
L. A. Kotilinek, M. A. Westerman, Q. Wang, K. Panizzon, G. P. Lim, A. Simonyi, S. Lesne, A. Falinska, L. H. Younkin, S. G. Younkin, et al.
Cyclooxygenase-2 inhibition improves amyloid-{beta}-mediated suppression of memory and synaptic plasticity
Brain, March 1, 2008; 131(3): 651 - 664.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
C. Patterson MD, J. W. Feightner MD MSc, A. Garcia MD PhD, G.-Y. R. Hsiung MD MHSc, C. MacKnight MD MSc, and A. D. Sadovnick PhD
Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease
Can. Med. Assoc. J., February 26, 2008; 178(5): 548 - 556.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
C. A. Szekely, J.C.S. Breitner, A. L. Fitzpatrick, T. D. Rea, B. M. Psaty, L. H. Kuller, and P. P. Zandi
NSAID use and dementia risk in the Cardiovascular Health Study*: Role of APOE and NSAID type
Neurology, January 1, 2008; 70(1): 17 - 24.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. M. Mielke, P. B. Rosenberg, J. Tschanz, L. Cook, C. Corcoran, K. M. Hayden, M. Norton, P. V. Rabins, R. C. Green, K. A. Welsh-Bohmer, et al.
Vascular factors predict rate of progression in Alzheimer disease
Neurology, November 6, 2007; 69(19): 1850 - 1858.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. M. Scharf and K. R. Daffner
NSAIDs in the prevention of dementia: A Cache-22?
Neurology, July 17, 2007; 69(3): 235 - 236.
[Full Text] [PDF]

Home page
 NeurologyHome page
K. M. Hayden, P. P. Zandi, A. S. Khachaturian, C. A. Szekely, M. Fotuhi, M. C. Norton, J. T. Tschanz, C. F. Pieper, C. Corcoran, C. G. Lyketsos, et al.
Does NSAID use modify cognitive trajectories in the elderly?: The Cache County Study
Neurology, July 17, 2007; 69(3): 275 - 282.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. A. Culbert, S. D. Skaper, D. R. Howlett, N. A. Evans, L. Facci, P. E. Soden, Z. M. Seymour, F. Guillot, M. Gaestel, and J. C. Richardson
MAPK-activated Protein Kinase 2 Deficiency in Microglia Inhibits Pro-inflammatory Mediator Release and Resultant Neurotoxicity: RELEVANCE TO NEUROINFLAMMATION IN A TRANSGENIC MOUSE MODEL OF ALZHEIMER DISEASE
J. Biol. Chem., August 18, 2006; 281(33): 23658 - 23667.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
F. Yang, G. P. Lim, A. N. Begum, O. J. Ubeda, M. R. Simmons, S. S. Ambegaokar, P. P. Chen, R. Kayed, C. G. Glabe, S. A. Frautschy, et al.
Curcumin Inhibits Formation of Amyloid {beta} Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo
J. Biol. Chem., February 18, 2005; 280(7): 5892 - 5901.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
P. P. Zandi, D. L. Sparks, A. S. Khachaturian, J. Tschanz, M. Norton, M. Steinberg, K. A. Welsh-Bohmer, J. C. S. Breitner, and for the Cache County Study Investigators
Do Statins Reduce Risk of Incident Dementia and Alzheimer Disease?: The Cache County Study
Arch Gen Psychiatry, February 1, 2005; 62(2): 217 - 224.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
A. J. M. de Craen, J. Gussekloo, B. Vrijsen, and R. G. J. Westendorp
Meta-Analysis of Nonsteroidal Antiinflammatory Drug Use and Risk of Dementia
Am. J. Epidemiol., January 15, 2005; 161(2): 114 - 120.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
K. Yaffe, A. Kanaya, K. Lindquist, E. M. Simonsick, T. Harris, R. I. Shorr, F. A. Tylavsky, and A. B. Newman
The Metabolic Syndrome, Inflammation, and Risk of Cognitive Decline
JAMA, November 10, 2004; 292(18): 2237 - 2242.
[Abstract] [Full Text] [PDF]

Home page
 Sci Aging Knowl EnvironHome page
P. L. McGeer and E. McGeer
Immunotherapy for Alzheimer's Disease
Sci. Aging Knowl. Environ., July 7, 2004; 2004(27): pe29 - pe29.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
L. Gan, S. Ye, A. Chu, K. Anton, S. Yi, V. A. Vincent, D. von Schack, D. Chin, J. Murray, S. Lohr, et al.
Identification of Cathepsin B as a Mediator of Neuronal Death Induced by A{beta}-activated Microglial Cells Using a Functional Genomics Approach
J. Biol. Chem., February 13, 2004; 279(7): 5565 - 5572.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
W. Qin, L. Ho, P. N. Pompl, Y. Peng, Z. Zhao, Z. Xiang, N. K. Robakis, J. Shioi, J. Suh, and G. M. Pasinetti
Cyclooxygenase (COX)-2 and COX-1 Potentiate {beta}-Amyloid Peptide Generation through Mechanisms That Involve {gamma}-Secretase Activity
J. Biol. Chem., December 19, 2003; 278(51): 50970 - 50977.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
C. Benito, E. Nunez, R. M. Tolon, E. J. Carrier, A. Rabano, C. J. Hillard, and J. Romero
Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains
J. Neurosci., December 3, 2003; 23(35): 11136 - 11141.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
T. E. Strandberg, K. H. Pitkala, K. H. Linnavuori, and R. S. Tilvis
Impact of Viral and Bacterial Burden on Cognitive Impairment in Elderly Persons With Cardiovascular Diseases
Stroke, September 1, 2003; 34(9): 2126 - 2131.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. A. Sagi, S. Weggen, J. Eriksen, T. E. Golde, and E. H. Koo
The Non-cyclooxygenase Targets of Non-steroidal Anti-inflammatory Drugs, Lipoxygenases, Peroxisome Proliferator-activated Receptor, Inhibitor of {kappa}B Kinase, and NF{kappa}B, Do Not Reduce Amyloid {beta}42 Production
J. Biol. Chem., August 22, 2003; 278(34): 31825 - 31830.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
M. Etminan, S. Gill, and A. Samii
Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies
BMJ, July 17, 2003; 327(7407): 128.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. C. Salzberg-Brenhouse, E.-Y. Chen, D. F. Emerich, S. Baldwin, K. Hogeland, S. Ranelli, D. Lafreniere, B. Perdomo, L. Novak, T. Kladis, et al.
Inhibitors of Cyclooxygenase-2, but Not Cyclooxygenase-1 Provide Structural and Functional Protection against Quinolinic Acid-Induced Neurodegeneration
J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 218 - 228.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. Hee Kang and F. Grodstein
Regular use of nonsteroidal anti-inflammatory drugs and cognitive function in aging women
Neurology, May 27, 2003; 60(10): 1591 - 1597.
[Abstract] [Full Text] [PDF]


Advertisement